BrioHealth Solutions has commenced subject enrolment in the US for the randomised INNOVATE trial, which will assess the BrioVAD system in treating refractory left ventricular heart failure. The ...
BURLINGTON, Mass., April 24, 2026 /PRNewswire/ -- BrioHealth Solutions (www.briohealthsolutions.com) announced that it has received FDA conditional approval to initiate a clinical evaluation of the ...
BrioHealth Solutions has secured conditional approval from the US Food and Drug Administration (FDA) to initiate a clinical trial of its BrioVAD system in children diagnosed with advanced heart ...
BURLINGTON, Mass., March 17, 2026 /PRNewswire/ -- BrioHealth Solutions (www.briohealthsolutions.com) today announces the successful implantation of its 100th BrioVAD System, an investigational ...
BURLINGTON, Mass., Dec. 22, 2025 /PRNewswire/ -- BrioHealth Solutions announces it has reached a major milestone with the 100th enrollment in the INNOVATE Trial of the BrioVAD ® System, a Left ...
BrioHealth Solutions, Inc. announced today an official name change from CH Biomedical (USA) to BrioHealth Solutions, unveiling a new corporate identity that aligns with its mission to expand ...
BrioHealth Solutions has received FDA Investigational Device Exemption (IDE) approval to start enrollment in its Innovate clinical trial assessing the effectiveness and safety of the BioVAD System for ...
On Nov. 18, the heart failure and transplantation team at Emory University Hospital (EUH) made history, performing the first-ever surgical implantation in the United States of a brand-new type of ...
The MarketWatch News Department was not involved in the creation of this content. BURLINGTON, Mass., Dec. 22, 2025 /PRNewswire/ -- BrioHealth Solutions announces it has reached a major milestone with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results